CASRAI Dictionary

Tag: research misconduct federal funding

  • Research Misconduct Federal Funding: Grant Risk

    When an allegation of research misconduct is opened against a federally funded project, the grant does not simply continue as normal. The funding agency can defer draw-downs, restrict how funds are spent, or suspend the award outright, while the awardee institution — not the agency — conducts the inquiry and investigation under research misconduct federal funding rules that require prompt notification, safeguarding of funds, and, if misconduct is confirmed, cost recovery or debarment.

    Research misconduct is fabrication, falsification, or plagiarism in proposing, performing, or reviewing federally funded research, or in reporting its results — a definition set by the Office of Science and Technology Policy’s 2000 Federal Policy on Research Misconduct (65 Fed. Reg. 76,260) and applied by every major federal research funder.

    What Is Research Misconduct Under Federal Policy?

    Federal research misconduct policy applies a single, government-wide standard: fabrication, falsification, or plagiarism (FFP) committed in proposing, performing, or reviewing federally funded research, or in reporting its results. Under the OSTP Federal Policy on Research Misconduct, a finding requires proof that the conduct represents “a significant departure from accepted practices,” was committed “intentionally, or knowingly, or recklessly,” and is established “by a preponderance of the evidence” — a civil, not criminal, standard.

    Honest error and legitimate differences of scientific opinion are explicitly excluded. The policy also does not cover authorship disputes, harassment, or general grant-management violations, which fall under separate institutional or agency processes.

    • Fabrication — making up data or results and recording or reporting them.
    • Falsification — manipulating materials, equipment, or data so the research record is not accurately represented.
    • Plagiarism — appropriating another person’s ideas, processes, results, or words without credit.

    What Happens to Grant Funds During an Investigation?

    A grant under a misconduct inquiry does not automatically stop, but the funding agency retains authority to take interim administrative actions to protect federal funds while the institution investigates. These typically include deferring decisions on continued funding, restricting the purposes for which existing funds may be spent, requiring special award certifications, or — where the risk is severe — suspending the active award pending outcome.

    Responsibility for the investigation sits primarily with the recipient institution, not the funder. Under Public Health Service (PHS) rules governing NIH-funded research (42 CFR Part 93), and the parallel National Science Foundation framework (45 CFR Part 689), the institution runs its own inquiry and investigation while the agency monitors, can intervene, and controls the purse strings throughout.

    Investigation stage Typical fund status Who acts
    Institutional assessment / inquiry Funds usually continue; agency may be informed Research Integrity Officer (RIO)
    Formal investigation opened Agency may defer, restrict, or condition funding Institution investigates; ORI or NSF OIG notified
    Investigation concluded, misconduct found Suspension, termination, or debarment possible Agency Inspector General / Deciding Official

    Who Must Notify the Funding Agency, and When?

    Every institution receiving PHS or NSF funding is required, as a condition of its funding assurance, to notify the relevant federal office once a formal investigation is opened. For NIH and other Public Health Service awards, that notice goes to HHS’s Office of Research Integrity (ORI); for NSF awards, it goes to the NSF Office of Inspector General (OIG).

    Notification cannot wait for the case to close. If the institution determines during an inquiry or investigation that public health or safety is at risk, that federal interests or resources are threatened, that research activities should be suspended, or that there is a reasonable indication of a possible civil or criminal law violation, it must notify the agency immediately — not at the standard reporting milestones.

    • Immediate notice — health/safety risk, threat to federal resources, or suspected civil/criminal violation.
    • Formal notice at investigation opening — required under the institution’s PHS or NSF assurance.
    • Closing report — the full institutional record, transmitted to ORI or NSF OIG after a final misconduct determination and any institutional appeal.

    What Are the Consequences If Misconduct Is Confirmed?

    If an investigation substantiates research misconduct, the funding agency can impose administrative sanctions independent of, and in addition to, any action the institution itself takes. Under ORI’s guidance on federal policy, “the Federal Government can debar researchers who commit misconduct from receiving Federal funds for a specified period of time,” and institutions commonly pursue their own parallel actions such as termination of employment or mandated supervision of future work.

    Available federal administrative actions include:

    • Correction of the published research record and retraction of affected papers.
    • Letters of reprimand or special certification requirements on future awards.
    • Suspension or termination of the active award, with recovery of misspent federal funds.
    • Suspension or debarment from federal funding, published on the General Services Administration’s SAM.gov exclusions list.
    • Referral to the Department of Justice where civil or criminal fraud is suspected.

    Cost recovery is a distinct lever from debarment: an institution can be required to repay funds tied to fabricated or falsified data even where an individual researcher, not the institution, is the primary respondent.

    How Does the 2024 Final Rule Change the Process?

    The compliance landscape shifted materially with HHS’s Final Rule updating 42 CFR Part 93, published in the Federal Register on 17 September 2024 and formally titled “Public Health Service Policies on Research Misconduct.” The rule took effect 1 January 2025, but institutions were required to apply its new procedural requirements to any allegation received on or after 1 January 2026, with updated institutional policies due to ORI no later than the annual report covering 2025 (filed by 30 April 2026).

    The Final Rule extends two of the timelines research administrators rely on most:

    • Inquiry period: extended from 60 days under the 2005 regulation to 90 days.
    • Investigation period: extended from 120 days under the 2005 regulation to 180 days.

    It also formalises a new pre-inquiry “institutional assessment” stage (§93.306), in which the Research Integrity Officer must document whether an allegation falls within the misconduct definition and PHS jurisdiction before an inquiry is opened — with no fixed time limit for this new stage. The rule further clarifies confidentiality obligations, allowing institutions to disclose respondent identities to journals, co-authors, and collaborating institutions where there is a legitimate need to know, and expands provisions covering multiple respondents and multi-institution proceedings.

    Frequently Asked Questions

    Does the Funding Agency Investigate Misconduct Directly, or Does the Institution?

    The institution conducts the initial inquiry and investigation, not the federal funding agency. Agencies such as ORI or the NSF OIG monitor the case, can intervene if the institution is unable or unwilling to act, and retain authority over the grant throughout.

    What Standard of Proof Applies to a Misconduct Finding?

    A finding requires proof “by a preponderance of the evidence” — more likely than not — not the criminal “beyond a reasonable doubt” standard. The conduct must also be shown to have been committed intentionally, knowingly, or recklessly, and to represent a significant departure from accepted research practice.

    What Is the First Phase of a Research Misconduct Response?

    The process begins with an institutional assessment or inquiry — a preliminary review to decide whether an allegation has enough substance to warrant a full investigation. Under the 2024 Final Rule, this assessment stage is now formally documented before any inquiry clock starts running.

    To Whom Does the Federal Research Misconduct Policy Apply?

    The policy applies to anyone proposing, performing, or reviewing federally funded research — including applicants, grant recipients, subrecipients, project participants, and peer reviewers — at any institution receiving Public Health Service or comparable federal research funding.

    Implications for Research Administrators

    The practical exposure is threefold: a live award can be frozen or restricted mid-project, cost recovery can claw back funds already spent, and delayed or incomplete notification to the funder is a compliance failure in its own right, separate from the underlying allegation. Research integrity offices should treat the 2026 compliance deadline as a trigger to audit their policies against the extended 90/180-day timelines and the new institutional-assessment stage — a policy still reflecting the 2005 regulation’s 60/120-day clock no longer matches what ORI expects in an institutional record.

    The Final Rule’s added reporting elements — sequestration inventories, interview transcripts, and multi-institution coordination — point toward longer, more paperwork-intensive proceedings even as deadlines extend. For anyone administering federally funded research, what happens to the grant while a case runs is as important as the underlying definition of misconduct itself.

  • Research Misconduct GCP vs ORI: Key Differences

    Research misconduct GCP rules cover more ground than the academic misconduct standard researchers may already know. Under FDA bioresearch-monitoring (BIMO) authority and Good Clinical Practice, misconduct in a clinical trial can include protocol violations, unprotected human subjects and data-integrity failures — not only fabrication, falsification or plagiarism. This creates a parallel compliance track that runs alongside, and sometimes collides with, the Office of Research Integrity’s (ORI) Public Health Service (PHS) misconduct policy.

    Research misconduct, under 42 CFR Part 93, is defined by ORI as “fabrication, falsification, or plagiarism in proposing, performing, or reviewing research, or in reporting research results” — committed intentionally, knowingly, or recklessly, and representing a significant departure from accepted practice. GCP misconduct, by contrast, is judged against compliance with the trial protocol, informed-consent rules and data-integrity requirements set out in FDA regulations, and does not hinge on the same intent test.

    What Counts as Research Misconduct Under FDA and GCP Rules?

    FDA’s Bioresearch Monitoring programme inspects clinical investigators, sponsors, monitors and institutional review boards for compliance with clinical trial regulations, principally 21 CFR Parts 50, 56 and 312 and the internationally harmonised ICH E6(R2) Good Clinical Practice guideline. Misconduct in this context extends well beyond fabrication, falsification and plagiarism (FFP).

    It can include failing to protect human subjects, proceeding without valid informed consent, deviating repeatedly from the approved protocol, or under-reporting adverse events. FDA inspectors have described a lower practical bar for sanction than the PHS intent standard: repeated or negligent noncompliance with GCP can itself justify action, even without proof of deliberate deception.

    How Does ORI/PHS Academic Misconduct Policy Differ?

    ORI oversees institutions receiving PHS funding — chiefly NIH grants — under the narrower FFP definition. A finding requires evidence of intent (“intentionally, knowingly, or recklessly”) and a significant departure from accepted research practice. Honest error and genuine differences of scientific opinion are explicitly excluded.

    The table below sets out the core distinctions between the two frameworks.

    Dimension ORI/PHS academic policy FDA GCP/BIMO framework
    Core definition Fabrication, falsification, plagiarism (FFP) FFP plus GCP deviations: consent failures, protocol breaches, data-integrity gaps
    Governing rule 42 CFR Part 93 21 CFR Parts 50, 56, 312; ICH E6(R2)
    Intent threshold Intentional, knowing or reckless; “significant departure” Can extend to negligent or repeated noncompliance
    Jurisdiction PHS-funded research only Any trial data submitted to FDA in a marketing application, funded or not
    Investigator Institutional integrity officer, ORI oversight FDA Office of Scientific Investigations / BIMO inspectors
    Typical sanction Federal funding debarment, supervision, record correction Clinical investigator disqualification (21 CFR 312.70), data rejection, debarment

    The practical consequence: a fully compliant academic institution can still have a GCP problem, and a well-run industry trial with no PHS funding at all is entirely outside ORI’s remit but squarely inside FDA’s.

    What Triggers an FDA Bioresearch-Monitoring Investigation?

    BIMO inspections are risk-based and routine as well as complaint-driven. FDA selects clinical investigator sites for inspection using data anomalies, unusually favourable results, high enrolment rates, complaints, or as a standard check ahead of marketing-application review.

    • Falsified or fabricated case-report-form data submitted in an IND or NDA;
    • Repeated protocol deviations affecting subject safety or data validity;
    • Informed-consent documentation failures under 21 CFR Part 50;
    • Institutional review board oversight lapses under 21 CFR Part 56;
    • Undisclosed financial conflicts of interest affecting trial conduct.

    Confirmed findings can lead to disqualification of a clinical investigator under 21 CFR 312.70, rejection of the affected data from a submission, referral for criminal prosecution, or debarment under the Federal Food, Drug, and Cosmetic Act’s Application Integrity Policy.

    What Happens When a Trial Falls Under Both Frameworks?

    Many clinical trials are simultaneously NIH-funded (triggering PHS/ORI jurisdiction) and submitted to FDA in support of an IND or marketing application (triggering GCP/BIMO jurisdiction). In that scenario, a single allegation can spawn two parallel investigations, run by different bodies, applying different definitions, evidentiary thresholds and remedies.

    ORI’s process centres on correcting the scientific record and imposing funding-related sanctions on the individual researcher. FDA’s process centres on protecting trial subjects and the integrity of data submitted for regulatory approval, and can act against a sponsor, monitor or institution as well as an investigator. Research administrators managing multi-funded trials need policies that map obligations under both tracks, since satisfying one does not discharge the other.

    For institutions, the practical implication is a dual-reporting duty: allegations touching FDA-regulated data may need parallel notification to the institution’s research integrity officer and, where applicable, to the FDA sponsor or IND holder — a distinction general research-misconduct training rarely covers.

    Frequently Asked Questions

    What are the three types of research misconduct?

    Under ORI/PHS policy, the three recognised types are fabrication (making up data), falsification (manipulating materials or omitting results) and plagiarism (using others’ work without credit) — collectively known as FFP. FDA/GCP rules recognise these plus separate categories tied to human-subject protection and protocol compliance.

    What counts as research misconduct?

    Research misconduct is conduct that deliberately or recklessly falls short of accepted research standards, spanning proposal, conduct and reporting. Under GCP, it also covers protocol deviations, invalid consent and unreported adverse events — behaviours the narrower academic FFP definition does not automatically capture.

    What are some examples of research misconduct?

    Examples include fabricating patient outcomes, falsifying case-report-form entries, plagiarising a manuscript, enrolling subjects without valid informed consent, and concealing a serious adverse event from a sponsor or IRB. The last three are GCP-specific failures with no direct ORI/PHS equivalent.

    What are the 5 unethical practices in research?

    Commonly cited categories are falsification of data, failure to credit others, plagiarism, undisclosed conflicts of interest, and biased design or interpretation. In FDA-regulated trials, a sixth practical category applies: noncompliance with GCP itself, regardless of intent.

    As FDA-regulated trials grow more complex and more federally co-funded research crosses into the BIMO’s remit, institutions running clinical research increasingly need compliance frameworks built to satisfy both standards concurrently, rather than treating GCP obligations as an addendum to existing academic misconduct policy. Building that dual-track literacy into institutional training is the clearest way to close the gap this comparison exposes.

    For related institutional context, see CASRAI’s overview of research administration compliance frameworks and the research integrity dictionary for definitions of adjacent terms.